Non-Metastatic Castration Resistant Prostate Cancer Treatment Market Share

North American Market Forecast   

North America industry is anticipated to dominate majority revenue share of 30% by 2037, The growth of the market can be attributed majorly to the increasing awareness about nmCRPC and the need to develop innovative cancer treatment solutions in the region. Furthermore, in 2021, the market in North America was expected to hold the largest share in terms of revenue, owing to the growing investment of governmental and non-governmental agencies in cancer screening & research, accompanied by the presence of leading healthcare service providers in the region. Along with this, North America also leads in terms of ongoing clinical trials, which is also expected to contribute to the market growth in the region. North America is known to be the most prevalent region of cancer. For instance, as of 2018, out of 1 million cancer cases, around 12% of them were projected to be prostate cancer in North America. 

Europe Market Forecast

The European non-metastatic castration resistant prostate cancer (nmCRPC) treatment market, amongst the market in all the other regions, is projected to hold the second largest share during the forecast period. the market in Europe is also anticipated to occupy a significant share in the mnCRPC treatment market on account of its proven success in terms of drug development and the high incidence of prostate cancer in the region. As per the analysis of the European Commission, prostate cancer is ranked first among the most widely diagnosed cancer among men in the European Union. For instance, it was estimated that approximately 50,000 new prostate cancer are diagnosed in the United Kingdom every year which sums up to 135 cases every day. Apart from that, nearly 12,000 people died owing to prostate cancer in the region between 2017-2029. Hence, all these statistics about prostate cancer are estimated to expand the market size over the forecast period.